The CSNK2A2 antibody targets the protein encoded by the *CSNK2A2* gene, which is a subunit of the Casein Kinase 2 (CK2) enzyme complex. CK2 is a ubiquitously expressed serine/threonine kinase involved in diverse cellular processes, including cell proliferation, apoptosis, DNA repair, and signal transduction. The CK2 holoenzyme typically consists of two catalytic subunits (α or α', encoded by *CSNK2A1* and *CSNK2A2*, respectively) and two regulatory β subunits. The α' subunit (CSNK2A2) shares high sequence homology with the α subunit but exhibits distinct expression patterns and functional roles in certain contexts.
Antibodies against CSNK2A2 are widely used to study its expression, localization, and activity in physiological and pathological conditions. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research highlights CK2's involvement in cancer, where its overexpression is linked to tumor progression and therapy resistance, making CSNK2A2 a potential therapeutic target. Additionally, CSNK2A2-specific antibodies help explore CK2's role in neurodegenerative diseases, viral infections, and developmental processes. Validation of these antibodies is critical to ensure specificity, given the structural similarity between α and α' subunits. Overall, CSNK2A2 antibodies serve as essential tools for dissecting CK2 biology and its implications in disease mechanisms.